Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Maintenance in MIBC
NCT05072600Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Peking University First Hospital. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05072600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072600.